Blood Coagulation Disorders, Inherited - 26 Studies Found
Recruiting |
: Evaluation of Hemostasis in Bleeding and Thrombotic Disorders :
: 2005-09-12 |
Recruiting |
: Education Program for Patients Receiving Oral Anticoagulation :
|
Recruiting |
: A Gene Transfer Study for Hemophilia A : Hemophilia A : 2016-12-16 : Genetic: SPK-8011 A novel, bio-engineered, recombinant adeno-associated viral vector carrying human fact |
Withdrawn |
: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B : Hemophilia B : 2013-11-14 : Biological: IB1001 Prophylaxis (during Treatment and Conti |
Not yet recruiting |
: Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients : Antithrombin Deficiency Type 2 : 2017-03-21 : Drug: ATryn continuous infusion replenish serum thrombin levels |
Completed |
: BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) :
: 2007-12-21 : Drug: Kogenate (BAY14-2222) One group two treatment schedules, first on-demand then switch to prophylaxi |
Completed |
: Epidemiology and Immunology of Hemophilia A Inhibitors :
: 2000-05-25 |
Terminated |
: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery : Thrombophilia Due to Acquired Antithrombin III Deficiency : 2012-02-07 : Drug: Recombinant antithrombin (rhAT) Subjects will receive an intravenous bolus of 500 units of recombi |
Not yet recruiting |
: Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies : Hemophilia : 2017-05-16 : Other: Non interventionnal study A query form to all concerned patients by each investigating centre wil |
Available |
: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors : Hemophilia A : 2017-05-12 : Biological: Emicizumab Participants will receive emicizumab at a loading dose of 3 milligrams per kilogr |